Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2

Kuan Der Lee, Hsin Wei Chen, Chih G. Chen, Yan Chung Shih, Hsing Kun Liu, Mei Lien Cheng

Research output: Contribution to journalArticle

Abstract

T cells can be activated in vitro by monoclonal antibodies to CD3 (anti-CD3) to become non-MHC restricted killer cells (CD3-AK). Anti-CD3 activation upregulates the expression of the interleukin (IL)-2 receptors on T cells whose expansion is facilitated by IL-2. The therapeutic effect of in vivo administration of anti-CD3 and IL-2 has been investigated in many types of human cancers. To circumvent the toxicities posed by systemic administration of high-dose IL-2, there is interest in forming a strategy for targeting and concentrating IL-2 at the site where it is needed. This study investigates the feasibility of constructing a novel fusion protein consisting of IL-2 fused to the constant region of anti-CD3 antibody. Our results indicate that the specific IL-2 receptor-binding capability and bioactivity of the IL-2 portion as well as the CD3-binding and biological functions of anti-CD3 portion remain intact in this anti-CD3/IL-2 fusion protein. Thus, cytokines fused to anti-CD3 antibody by genetic engineering is feasible and may provide a new class of immunotherapeutics for cancer.

Original languageEnglish
Pages (from-to)1211-1216
Number of pages6
JournalOncology Reports
Volume15
Issue number5
Publication statusPublished - May 2006
Externally publishedYes

Fingerprint

Interleukin-2
Antibodies
Proteins
Interleukin-2 Receptors
T-Lymphocytes
Genetic Engineering
Feasibility Studies
Therapeutic Uses
Neoplasms
Up-Regulation
Monoclonal Antibodies
Cytokines

Keywords

  • Anti-CD3
  • Fusion protein
  • IL-2

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2. / Lee, Kuan Der; Chen, Hsin Wei; Chen, Chih G.; Shih, Yan Chung; Liu, Hsing Kun; Cheng, Mei Lien.

In: Oncology Reports, Vol. 15, No. 5, 05.2006, p. 1211-1216.

Research output: Contribution to journalArticle

Lee, Kuan Der ; Chen, Hsin Wei ; Chen, Chih G. ; Shih, Yan Chung ; Liu, Hsing Kun ; Cheng, Mei Lien. / Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2. In: Oncology Reports. 2006 ; Vol. 15, No. 5. pp. 1211-1216.
@article{8edec568e37c407b8f0e685887b94023,
title = "Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2",
abstract = "T cells can be activated in vitro by monoclonal antibodies to CD3 (anti-CD3) to become non-MHC restricted killer cells (CD3-AK). Anti-CD3 activation upregulates the expression of the interleukin (IL)-2 receptors on T cells whose expansion is facilitated by IL-2. The therapeutic effect of in vivo administration of anti-CD3 and IL-2 has been investigated in many types of human cancers. To circumvent the toxicities posed by systemic administration of high-dose IL-2, there is interest in forming a strategy for targeting and concentrating IL-2 at the site where it is needed. This study investigates the feasibility of constructing a novel fusion protein consisting of IL-2 fused to the constant region of anti-CD3 antibody. Our results indicate that the specific IL-2 receptor-binding capability and bioactivity of the IL-2 portion as well as the CD3-binding and biological functions of anti-CD3 portion remain intact in this anti-CD3/IL-2 fusion protein. Thus, cytokines fused to anti-CD3 antibody by genetic engineering is feasible and may provide a new class of immunotherapeutics for cancer.",
keywords = "Anti-CD3, Fusion protein, IL-2",
author = "Lee, {Kuan Der} and Chen, {Hsin Wei} and Chen, {Chih G.} and Shih, {Yan Chung} and Liu, {Hsing Kun} and Cheng, {Mei Lien}",
year = "2006",
month = "5",
language = "English",
volume = "15",
pages = "1211--1216",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2

AU - Lee, Kuan Der

AU - Chen, Hsin Wei

AU - Chen, Chih G.

AU - Shih, Yan Chung

AU - Liu, Hsing Kun

AU - Cheng, Mei Lien

PY - 2006/5

Y1 - 2006/5

N2 - T cells can be activated in vitro by monoclonal antibodies to CD3 (anti-CD3) to become non-MHC restricted killer cells (CD3-AK). Anti-CD3 activation upregulates the expression of the interleukin (IL)-2 receptors on T cells whose expansion is facilitated by IL-2. The therapeutic effect of in vivo administration of anti-CD3 and IL-2 has been investigated in many types of human cancers. To circumvent the toxicities posed by systemic administration of high-dose IL-2, there is interest in forming a strategy for targeting and concentrating IL-2 at the site where it is needed. This study investigates the feasibility of constructing a novel fusion protein consisting of IL-2 fused to the constant region of anti-CD3 antibody. Our results indicate that the specific IL-2 receptor-binding capability and bioactivity of the IL-2 portion as well as the CD3-binding and biological functions of anti-CD3 portion remain intact in this anti-CD3/IL-2 fusion protein. Thus, cytokines fused to anti-CD3 antibody by genetic engineering is feasible and may provide a new class of immunotherapeutics for cancer.

AB - T cells can be activated in vitro by monoclonal antibodies to CD3 (anti-CD3) to become non-MHC restricted killer cells (CD3-AK). Anti-CD3 activation upregulates the expression of the interleukin (IL)-2 receptors on T cells whose expansion is facilitated by IL-2. The therapeutic effect of in vivo administration of anti-CD3 and IL-2 has been investigated in many types of human cancers. To circumvent the toxicities posed by systemic administration of high-dose IL-2, there is interest in forming a strategy for targeting and concentrating IL-2 at the site where it is needed. This study investigates the feasibility of constructing a novel fusion protein consisting of IL-2 fused to the constant region of anti-CD3 antibody. Our results indicate that the specific IL-2 receptor-binding capability and bioactivity of the IL-2 portion as well as the CD3-binding and biological functions of anti-CD3 portion remain intact in this anti-CD3/IL-2 fusion protein. Thus, cytokines fused to anti-CD3 antibody by genetic engineering is feasible and may provide a new class of immunotherapeutics for cancer.

KW - Anti-CD3

KW - Fusion protein

KW - IL-2

UR - http://www.scopus.com/inward/record.url?scp=33745004193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745004193&partnerID=8YFLogxK

M3 - Article

C2 - 16596189

AN - SCOPUS:33745004193

VL - 15

SP - 1211

EP - 1216

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -